Gemox Chemotherapy, Intrahepatic Cholangiocarcinoma, Lenvatinib, PD1 Antibody
Conditions
Brief summary
A randomized controlled, multicenter, open, seamless phase II-III clinical trial is designed to target patients with resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors which has extremely low postoperative recurrence-free survival. In this study, we aim to compare the prognosis in intrahepatic cholangiocarcinoma between Toripalimab combined with leventinib and GEMOX neoadjuvant treatment and the current clinical surgical treatment (traditional group).
Detailed description
Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor of biliary epithelial cells that originates from the branches of the intrahepatic bile duct at the second level and above. Its incidence accounts for about 15%-20% of primary liver malignancies, showing a gradual increase trend. Surgical resection is currently the main method for the treatment of ICC. The data of a large number of ICC cases shows that even radical resection (R0) patients have an average survival of only 18.3 months, while for palliative resection patients, the average survival is only 6.6 months, and laparotomy patients only 5.6 months. Retrospective studies reported that positive resection margins, lymph node metastasis, lymphatic vessel invasion, nerve bundle invasion, preoperative CA199\>200U/ml, multiple tumor nodules and differentiation are the main factors affecting the survival of ICC patients after surgery. How to improve the surgical results of ICC patients, especially those with high risk factors for postoperative recurrence, is an important way to improve the overall survival of ICC. Neoadjuvant therapy refers to some treatments taken before surgery for newly treated tumor patients who have not found distant metastasis, including chemotherapy, radiotherapy, targeted therapy, etc., to reduce tumor size, reduce tumor stages, and reduce postoperative recurrence rate, prolonging survival time. Our previous study using Toripalimab combined with lenvatinib and Gemox chemotherapy in the first-line treatment of unresectable advanced cholangiocarcinoma (NCT03951597,2020ESMO) showed that the ORR was 80% and the DCR reached 93.3%, of which 1 case was CR, 23 cases were PR, and 2 cases were successfully treated with radical resection after downstage. And the adverse reactions are controllable. These data suggest that Toripalimab combined with lenvatinib and Gemox chemotherapy may be an ideal neoadjuvant treatment for patients with resectable intrahepatic cholangiocarcinoma with high-risk recurrence factors, needing more investigation.
Interventions
DRUGNeoadjuvant treatment
PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
Sponsors
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Public Health Clinical Center
RenJi Hospital
Shenzhen University General Hospital
Sir Run Run Shaw Hospital
Tang-Du Hospital
First Affiliated Hospital of Wenzhou Medical University
The First Affiliated Hospital of Zhengzhou University
The First Affiliated Hospital of Anhui Medical University
First Hospital of China Medical University
Eastern Hepatobiliary Surgery Hospital
First Affiliated Hospital Xi'an Jiaotong University
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
First Affiliated Hospital of Guangxi Medical University
The Affiliated Hospital of Qingdao University
Peking Union Medical College Hospital
Meng Chao Hepatobiliary Hospital of Fujian Medical University
The First Affiliated Hospital of University of Science and Technology of China
Cancer Hospital of Guangxi Medical University
Tongji Hospital
Zhejiang Provincial People's Hospital
The Second Affiliated Hospital of Kunming Medical University
Sichuan Provincial People's Hospital
Taizhou Hospital
Shaoxing People's Hospital
The First Hospital of Hebei Medical University
Shanghai Zhongshan Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* 1\) Sign written informed consent 2) Male or female patients aged 18-70; 3) ECOG score 0 points, Child-Pugh rating A; 4) Pathological diagnosis by biopsy: Intrahepatic cholangiocarcinoma (ICC). 5) Resectable ICC patients with high risk factors for recurrence (tumor diameter\>5cm or imaging vascular invasion, multiple tumor nodules or hilar lymph node metastasis or Preoperative CA19-9 \>37 U/mL or above the upper limit of normal (for centers where the normal range is not \<37 U/mL); 6) The functional indicators of important organs meet the following requirements 1. Neutrophils≥1.5\*109/L; platelets≥90\*109/L; hemoglobin≥9g/dl; serum albumin≥3.5g/dl; 2. Coagulation function: International standardization (prothrombin time) ratio (INR) \<1.2; 3. T3 and T4 do not exceed the normal upper and lower limits by 2 times; 4. Bilirubin ≤ 1.5 times the upper limit of normal; ALT and AST ≤ 3 times the upper limit of normal; 5. Serum creatinine ≤ 1.5 times the upper limit of normal, creatinine clearance ≥ 60ml/min; 7) The subject has at least 1 measurable liver disease (according to RECIST1.1); 8) For women who are not breastfeeding or pregnant, use contraception during treatment or 3 months after the end of treatment.
Exclusion criteria
* 1\) Pathological diagnosis of hepatocellular carcinoma, mixed hepatocellular carcinoma and other non-biliary cell carcinoma malignant tumor components; 2) Patients who relapse after surgery, have received PD1 antibody, PDL1 antibody or CTLA4 antibody, lenvatinib, chemotherapy in the past; participated in other clinical trials 30 days before screening; 3) Past or simultaneous suffering from other malignant tumors, except for fully treated non-melanoma skin cancer, cervical carcinoma in situ and thyroid papillary carcinoma; 4) Active tuberculosis infection. Patients with active tuberculosis infection within 1 year before enrollment; a history of active tuberculosis infection more than 1 year before enrollment, no formal anti-tuberculosis treatment or tuberculosis is still active; 5) Suffer from active, known or suspected autoimmune diseases. Subjects with hypothyroidism who only need hormone replacement therapy and skin diseases without systemic therapy can be selected; 6) Past interstitial lung disease, or (non-infectious) pneumonia and need oral or intravenous steroid therapy; 7) Long-term use of systemic hormones (dose equivalent to \>10mg prednisone/day) or any other form of immunosuppressive therapy is required. Subjects using inhaled or topical corticosteroids can be selected; 8) Active infections that require systemic treatment; 9) Human immunodeficiency virus (HIV, HIV1/2 antibody) positive; 10) A history of psychotropic drug abuse, alcohol or drug abuse; 11) Significant clinically significant bleeding symptoms or a clear tendency to appear within 3 months before enrollment; 12) Suspected of being allergic to study drugs; 13) Suffer from hypertension, and cannot be well controlled by antihypertensive medication (systolic blood pressure ≥140mmHg or diastolic blood pressure ≥90mmHg); 14) After antiviral therapy, HBvDNA\>104 copies/ml, HCV RNA\>1000; 15) Accompanied by ascites, hepatic encephalopathy, Gilbert syndrome, sclerosing cholangitis, etc. Combined with insufficiency of other organs, it is expected that they cannot accept general anesthesia or hepatectomy; 16) Other factors judged by the investigator that may affect the safety of the subject or the compliance of the trial. Such as serious illnesses (including mental illness) that require combined treatment, serious laboratory abnormalities, or other family or social factors.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Event-free survival | 24 months | From randomization to the occurrence of the following events: disease progression prevents radical surgery; local or distant recurrence; second primary tumor; death due to various causes. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | 24 months | the time period from the randomization of the patient to the death event due to any reason |
| Objective response rate | 6 months | The proportion of patients whose tumor volume has decreased to a predetermined value |
| Pathological remission rate | 6 months | the ratio of the estimated active tumor size divided by the tumor bed size |
| R0 Resection Rate | 12 months | Curative Surgery Resection Rate |
| Recurrence-free survival | 24 months | the time from surgery to disease recurrence or all-cause death |
| Adverse events | 12 months | the severity of adverse events will be evaluated according to the NCI CTCAE 5.0 standard |
Other
| Measure | Time frame | Description |
|---|---|---|
| Exploratory markers | 24 months | the relationship between treatment response and clinical factors: carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), carbohydrate antigen 125 (CA125), tumor mutation burden (TMB), PD-L1 expression, microsatellite instability (MSI), dynamic changes of PET-CT Standard uptake value, dynamic changes of contrast Ultrasound and MRI |
Countries
China
Outcome results
None listed